Literature DB >> 9190320

[Review of current pharmacologic treatment of pain].

L Brasseur1.   

Abstract

Pain is the main reason prompting patients to consult their physicians. In acute conditions, pain has a very particular significance as a warning sign, enabling the physician to attempt a diagnosis. Nevertheless, its detrimental effect upon the individual (even in the case of acute pain) and its cost to society are now widely acknowledged. There can be no doubt about the physical component of pain, but the psychological and social aspects should not be ignored, particularly in the case of chronic pain. There is no single therapeutic approach to pain and, more often than not, successful treatment comprises a combination of several. Pharmacological treatments are undeniably the most common approach. In clinical practice, recent advances have been based upon an improved understanding of 'old' substances such as morphine and, at the same time, research continues in the hope of finding the 'ideal' analgesic-effective in most situations but without adverse effects: this appears to be a somewhat utopian arm at present, considering the number of different causes of pain. An improved understanding of the physiological mechanisms of pain has led, within the field of clinical practice, to several methods of differentiating pain. These depend on whether or not pain responds to morphine, or on the type of pain: pain due to an excess of nociception, pain resulting from deafferentation (caused by damage to nerve pathways) in the central or peripheral nervous system and psychogenic (idiopathic) pain. Likewise, there are several different ways of classifying analgesic treatments: according to the intensity of pain, as with use of the WHO ladder (which is based on the notion of steps) for the treatment of cancer pain; according to the presumed physiopathological mechanism and, in particular, the response to morphine, and according to the presumed central or peripheral mechanism of the drugs. In reality, peripherally acting drugs can also have a central mechanism of action, just as drugs known to have a central mechanism of action can also have peripheral activity. As a result, several therapeutic classes have been identified. Firstly NSAIDs, which act by inhibiting the enzymes that synthesise prostaglandins, cyclooxygenases (COX-1, COX-2), but which also act upon lipo-oxygenases: Their efficacy is interesting, although somewhat limited by both their ceiling effect and the frequent adverse gastrointestinal reactions they produce. Specific inhibitors of COX-2 could well reduce the risk of adverse effects. Opioids constitute the first-line treatment for pain, particularly severe pain. There are several classifications for these drugs. Firstly, weak opioids (such as codeine) and strong opioids (such as morphine) are differentiated. Secondly, a distinction is made between pure agonists (such as morphine), partial agonists (such as buprenorphine), agonist-antagonists (such as nalbuphine) and antagonists (such as naloxone). Finally, agents are distinguished on the basis of their chemical structure (synthetic, semi-synthetic or natural derivatives). These molecules act upon different receptors (mu, delta, kappa, sigma) and, although peripheral mechanisms have been described, their activity occurs mainly at spinal and supraspinal levels. They provide a potent analgesic effect but are also responsible for various adverse effects-nausea, vomiting, sedation, constipation and respiratory depression-which seriously limit their use. As long as the indication is appropriate, these drugs should not be withheld because of fear of dependence or abuse. It has been observed that other adjuvant therapeutic approaches, generally used to treat conditions other than pain, provide pain relief in certain situations. These include corticosteroids, which are-widely used in rheumatology and oncology, and antidepressants, which are frequently used to treat chronic pain, especially that with a neuropathic component. Anti-epileptics are also used, particularly for excrutiating

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9190320     DOI: 10.2165/00003495-199700532-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  32 in total

1.  Variations in response to non-steroidal anti-inflammatory drugs.

Authors:  R O Day; P M Brooks
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

2.  Pain, the physiological antagonist of opioid analgesics.

Authors:  G W Hanks; R G Twycross
Journal:  Lancet       Date:  1984-06-30       Impact factor: 79.321

Review 3.  Topical capsaicin as an adjuvant analgesic.

Authors:  C P Watson
Journal:  J Pain Symptom Manage       Date:  1994-10       Impact factor: 3.612

4.  Pimozide therapy for trigeminal neuralgia.

Authors:  F Lechin; B van der Dijs; M E Lechin; J Amat; A E Lechin; A Cabrera; F Gómez; E Acosta; L Arocha; S Villa
Journal:  Arch Neurol       Date:  1989-09

5.  Antidepressants and pain: a review of the pharmacological data supporting the use of certain tricyclics in chronic pain.

Authors:  R Lee; P S Spencer
Journal:  J Int Med Res       Date:  1977       Impact factor: 1.671

6.  Central analgesic effect of acetaminophen but not of aspirin.

Authors:  P Piletta; H C Porchet; P Dayer
Journal:  Clin Pharmacol Ther       Date:  1991-04       Impact factor: 6.875

7.  Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml.

Authors:  M Sjöberg; P Nitescu; L Appelgren; I Curelaru
Journal:  Anesthesiology       Date:  1994-02       Impact factor: 7.892

8.  Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.

Authors:  R S Ehsanullah; M C Page; G Tildesley; J R Wood
Journal:  BMJ       Date:  1988-10-22

9.  The use of oral mexiletine for the treatment of pain after peripheral nerve injury.

Authors:  C Chabal; L Jacobson; A Mariano; E Chaney; C W Britell
Journal:  Anesthesiology       Date:  1992-04       Impact factor: 7.892

10.  Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system.

Authors:  M Botney; H L Fields
Journal:  Ann Neurol       Date:  1983-02       Impact factor: 10.422

View more
  7 in total

1.  Nociceptive and neuropathic pain in patients with lung cancer: a comparison of pain quality descriptors.

Authors:  D J Wilkie; H Y Huang; N Reilly; K C Cain
Journal:  J Pain Symptom Manage       Date:  2001-11       Impact factor: 3.612

2.  Targeting MOR-mGluR5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5.

Authors:  Sarah S Shueb; Samuel J Erb; Mary M Lunzer; Rebecca Speltz; Catherine Harding-Rose; Eyup Akgün; Donald A Simone; Philip S Portoghese
Journal:  Neuropharmacology       Date:  2019-07-01       Impact factor: 5.250

3.  Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice.

Authors:  Phuong N Quang; Brian L Schmidt
Journal:  J Pain       Date:  2010-01-13       Impact factor: 5.820

4.  Buprederm, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies.

Authors:  In Park; Dongwon Kim; Jindeog Song; Chang Hoon In; Seung-Wei Jeong; Sang Hun Lee; Bumchan Min; Dongho Lee; Sun-Ok Kim
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

5.  Validation of the University of California San Francisco Oral Cancer Pain Questionnaire.

Authors:  Antonia Kolokythas; S Thaddeus Connelly; Brian L Schmidt
Journal:  J Pain       Date:  2007-08-07       Impact factor: 5.820

6.  Pharmacological Characterization of Orofacial Nociception in Female Rats Following Nitroglycerin Administration.

Authors:  Robert M Caudle; Stephanie L Caudle; Natalie D Flenor; Eric L Rohrs; John K Neubert
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

7.  Pharmacological strategies for the management of cancer pain in developing countries.

Authors:  Afekhide E Omoti; Caroline E Omoti
Journal:  Pharm Pract (Granada)       Date:  2007-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.